Skip to main content
main-content

18.12.2018 | Antikörper | International Research Highlight | Onlineartikel

International Research Highlight

Immunotherapy: New window of opportunity with ICIs in melanoma

Autor:
David Killock
Patients with resectable, stage III melanoma have a high risk of relapse after surgery. Thus, efforts have been made to improve outcomes using adjuvant therapies, historically immunotherapy with IFNα and more recently with immune-checkpoint inhibitors (ICIs), or targeted therapy for BRAFV600E/K-mutant disease. Now, three studies reveal that the presurgical setting provides a window of opportunity to improve patient outcomes with ICIs.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weiterführende Themen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise